| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KERA |
| Uniprot No | O60938 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-352aa |
| 氨基酸序列 | RSVRQVYEVH DSDDWTIHDF ECPMECFCPP SFPTALYCEN RGLKEIPAIP SRIWYLYLQN NLIETIPEKP FENATQLRWI NLNKNKITNY GIEKGALSQL KKLLFLFLED NELEEVPSPL PRSLEQLQLA RNKVSRIPQG TFSNLENLTL LDLQNNKLVD NAFQRDTFKG LKNLMQLNMA KNALRNMPPR LPANTMQLFL DNNSIEGIPE NYFNVIPKVA FLRLNHNKLS DEGLPSRGFD VSSILDLQLS HNQLTKVPRI SAHLQHLHLD HNKIKSVNVS VICPSPSMLP AERDSFSYGP HLRYLRLDGN EIKPPIPMAL MTCFRLLQAV II |
| 预测分子量 | 40,5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KERA重组蛋白的参考文献示例(注：以下为模拟内容，建议通过学术数据库查询真实文献)：
---
1. **文献名称**：*Expression and Purification of Recombinant Human Keratocan in E. coli*
**作者**：Zhang et al.
**摘要**：本研究通过大肠杆菌系统成功表达并纯化了重组人Keratocan(KERA)蛋白，采用His标签亲和层析技术获得高纯度蛋白，并通过Western blot和质谱验证其正确性，为后续功能研究奠定基础。
2. **文献名称**：*Functional Analysis of Recombinant KERA in Corneal Stroma Development*
**作者**：Li et al.
**摘要**：利用哺乳动物细胞表达系统制备重组KERA蛋白，发现其可促进角膜基质细胞中胶原纤维的有序排列，并通过调控TGF-β信号通路维持角膜透明度，提示其在角膜再生中的潜在应用。
3. **文献名称**：*High-Yield Production of Recombinant Keratocan in Pichia pastoris*
**作者**：Wang et al.
**摘要**：优化毕赤酵母表达系统实现重组KERA的高效分泌表达，产量达200 mg/L，且蛋白糖基化修饰与天然结构一致，为大规模生产提供可行方案。
4. **文献名称**：*Therapeutic Potential of Recombinant KERA in Corneal Dystrophy Models*
**作者**：Chen et al.
**摘要**：在小鼠角膜损伤模型中，局部应用重组KERA蛋白显著减少瘢痕形成，恢复角膜厚度和透明度，证实其作为生物治疗剂的可行性。
---
建议通过PubMed、ScienceDirect或Google Scholar检索关键词“recombinant KERA protein”“Keratocan expression”等获取真实文献。
**Background of KERA Recombinant Protein**
Keratocan (KERA), a key extracellular matrix protein, is predominantly expressed in the cornea and belongs to the small leucine-rich proteoglycan (SLRP) family. It plays a critical role in maintaining corneal transparency and structural integrity by regulating collagen fibril organization and interfibrillar spacing within the corneal stroma. Mutations in the *KERA* gene are linked to corneal dystrophies, such as autosomal recessive cornea plana (CNA2), characterized by reduced visual acuity and corneal flattening.
Recombinant KERA protein is engineered using biotechnological platforms (e.g., bacterial, yeast, or mammalian expression systems) to produce a purified, bioactive form of the protein. This recombinant variant retains functional domains essential for binding collagen and other stromal components, making it a valuable tool for studying corneal development, pathology, and repair mechanisms. Researchers utilize KERA recombinant protein to investigate its role in extracellular matrix assembly, cell adhesion, and signaling pathways implicated in corneal diseases.
In regenerative medicine, KERA holds therapeutic potential for restoring corneal transparency in degenerative conditions. It is also explored in bioengineered corneal implants and as a supplement in cell culture models to mimic the native stromal microenvironment. Additionally, recombinant KERA aids in drug screening and the development of targeted therapies for genetic corneal disorders. Its study bridges insights into both basic corneal biology and clinical applications, emphasizing its dual role as a structural regulator and a biomarker for corneal health.
×
